FR2854399A1 - 1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions les contenant et utilisation - Google Patents

1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions les contenant et utilisation

Info

Publication number
FR2854399A1
FR2854399A1 FR0305389A FR0305389A FR2854399A1 FR 2854399 A1 FR2854399 A1 FR 2854399A1 FR 0305389 A FR0305389 A FR 0305389A FR 0305389 A FR0305389 A FR 0305389A FR 2854399 A1 FR2854399 A1 FR 2854399A1
Authority
FR
France
Prior art keywords
indol
prop
aryl
ones
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0305389A
Other languages
English (en)
Other versions
FR2854399B1 (fr
Inventor
Patrick Mailliet
Fabienne Thompson
Luc Bertin
Gerard Leclere
Gilles Tiraboschi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to FR0305389A priority Critical patent/FR2854399B1/fr
Priority to PCT/FR2004/001012 priority patent/WO2004099193A2/fr
Priority to EP04742579A priority patent/EP1622895A2/fr
Priority to JP2006505814A priority patent/JP2006525291A/ja
Priority to US10/835,631 priority patent/US20040229931A1/en
Publication of FR2854399A1 publication Critical patent/FR2854399A1/fr
Application granted granted Critical
Publication of FR2854399B1 publication Critical patent/FR2854399B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1-Aryl-3-(indol-5-yl)-prop-2-èn-1-ones, compositions les contenant et utilisation. La présente invention concerne notamment de nouvelles 1-aryl-3-(indol-5-yl)-prop-2-èn-1-ones substituées ayant une activité thérapeutique, utilisables en particulier en oncologie.
FR0305389A 2003-04-30 2003-04-30 1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions les contenant et utilisation Expired - Lifetime FR2854399B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0305389A FR2854399B1 (fr) 2003-04-30 2003-04-30 1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions les contenant et utilisation
PCT/FR2004/001012 WO2004099193A2 (fr) 2003-04-30 2004-04-27 1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions les contenant et utilisation
EP04742579A EP1622895A2 (fr) 2003-04-30 2004-04-27 1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions les contenant et utilisation
JP2006505814A JP2006525291A (ja) 2003-04-30 2004-04-27 １−アリール−３−（インドール−５−イル）プロパ−２−エン−１−オン、該化合物を含む組成物、及びそれらの使用
US10/835,631 US20040229931A1 (en) 2003-04-30 2004-04-30 1-Aryl-3-(indol-5-yl) prop-2-en-1-ones, compositions containing them and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0305389A FR2854399B1 (fr) 2003-04-30 2003-04-30 1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions les contenant et utilisation

Publications (2)

Publication Number Publication Date
FR2854399A1 true FR2854399A1 (fr) 2004-11-05
FR2854399B1 FR2854399B1 (fr) 2006-11-17

Family

ID=33155601

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0305389A Expired - Lifetime FR2854399B1 (fr) 2003-04-30 2003-04-30 1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions les contenant et utilisation

Country Status (4)

Country Link
EP (1) EP1622895A2 (fr)
JP (1) JP2006525291A (fr)
FR (1) FR2854399B1 (fr)
WO (1) WO2004099193A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0680950A1 (fr) * 1993-11-17 1995-11-08 Kyowa Hakko Kogyo Co., Ltd. Derive de propenone
EP0770601A1 (fr) * 1995-05-10 1997-05-02 Kyowa Hakko Kogyo Co., Ltd. Derives de propenone
WO2003048106A2 (fr) * 2001-12-05 2003-06-12 Aventis Pharma S.A. 1,3-diarylprop-2-en-1-ones, compositions les contenant et utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0680950A1 (fr) * 1993-11-17 1995-11-08 Kyowa Hakko Kogyo Co., Ltd. Derive de propenone
EP0770601A1 (fr) * 1995-05-10 1997-05-02 Kyowa Hakko Kogyo Co., Ltd. Derives de propenone
WO2003048106A2 (fr) * 2001-12-05 2003-06-12 Aventis Pharma S.A. 1,3-diarylprop-2-en-1-ones, compositions les contenant et utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BECKERS ET AL.: "2-Aroylindoles, a Novel Class of Potent, Orally Active Small Molecule Tubulin Inhibitors", CANCER RESEARCH, vol. 62, 1 June 2002 (2002-06-01), pages 3113 - 3119, XP002267118 *

Also Published As

Publication number Publication date
FR2854399B1 (fr) 2006-11-17
WO2004099193A2 (fr) 2004-11-18
WO2004099193A3 (fr) 2005-01-06
JP2006525291A (ja) 2006-11-09
EP1622895A2 (fr) 2006-02-08

Similar Documents

Publication Publication Date Title
MA28664B1 (fr) Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
TNSN04175A1 (fr) Indazoles substitues avec une activite anticancereuse
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
SE0301653D0 (sv) Novel compounds
EA200100731A1 (ru) Фенилфенантридины с ингибирующей фдэ-4 активностью
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
MXPA03007527A (es) Enzimas que tienen actividad de alfa amilasa y metodos de uso de las mismas.
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
BRPI0512235A (pt) polipeptìdeos ligadores de antìgenos e seus usos
TW200519110A (en) Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use
BRPI0507118A (pt) polipeptìdeos de interferon humano modificado e seus usos
SE0301700D0 (sv) Novel compounds
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
BRPI0409367A (pt) derivados de piperidina inibidores de renina
DE602005017753D1 (de) Mittel für die transdermale verabreichung von nikotin
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
EA200602137A1 (ru) Гидрогелевые препараты интерферона
BRPI0413449A (pt) compostos de quinoxalina
ATE425982T1 (de) Thienopyrimidin-derivate als kaliumkanal- inhibitoren
PT1147103E (pt) Fenantridina-n-oxidos com actividade inibitoria de pde-iv
TW200531686A (en) Pharmaceutical compositions
UY3450Q (es) Botella